Trump officials are pushing psychedelic therapy. Will it help or hurt?
In the United States, a presidential administration finally seems to agree.
'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' US health secretary Robert F Kennedy Jr recently told members of Congress.
His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs.
The Trump administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants, and fluoride.
'I'm quite optimistic,' says Rick Doblin, whose organisation has pursed the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved'".
US regulators may reconsider MDMA
Under former US President Joe Biden, the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD), citing flawed data and questionable research.
Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first US approval of a psychedelic for medical use, and European researchers said it likely set the field back there as well.
But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval.
One new programme promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group.
That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill.
Links to psychedelic advocates
US health agencies also recently hired several new staffers with ties to the psychedelic movement.
'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies.
As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues.
But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science.
Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardise patients.
"If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.'
Nora Volkow, the longtime director of the US National Institute on Drug Abuse, said her agency remains interested in psychedelics. It is funding a US drugmaker that's working to develop a safer, synthetic version of ibogaine, which is a potent psychedelic made from a shrub that's native to West Africa.
Texas recently launched a $50 million (€42.7 million) trial to test ibogaine as a treatment for opioid addiction, PTSD, and other conditions.
'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said.
'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 days ago
- Euronews
EU regulators back climate-friendly inhaler
European regulators have given their backing to a new eco-friendly inhaler that could help curb health care's climate impact. Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD). These types of inhalers may be small, but they pack a powerful punch, producing the same type of greenhouse gas as air conditioning and heat pumps. In the United Kingdom, they cause 3 per cent of the National Health Service's (NHS) overall carbon emissions, according to Asthma + Lung UK. Many of these gases are now being phased out in the EU for environmental reasons, according to the European Medicines Agency (EMA). An EMA advisory committee issued a positive opinion of the new inhaler on Friday, and the European Commission, the EU's executive body, will make a final decision in the coming months. Other inhalers that do not use gas propellants are already available, and AstraZeneca's new model has a similarly low carbon footprint. The new option 'means patients and their clinicians now don't need to feel like they have to choose between the most appropriate treatment and the planet,' Pablo Panella, AstraZeneca's senior vice president of global respiratory and immunology, said in a written comment to Euronews Health. The new inhaler is already available in the United States, China, and Japan, and the United Kingdom signed off in May. AstraZeneca said it plans to transition its inhalers to the new model across the EU in the coming months, and that it hopes to roll the model out worldwide by 2030. The EMA said it 'works the same way and gives the same results in the lungs and the body [as] the product currently on the market'.
Euronews
2 days ago
- Euronews
EU Commission unlocks health funds but leaves civil society reeling from cuts
The European Commission this week finally unveiled its 2025 work programme for its €571 million health budget, EU4Health—a flagship initiative launched in response to the COVID-19 pandemic to strengthen public health across the bloc. The publication ended months of uncertainty and delay, with deep funding cuts already severely impacting NGOs and civil society groups operating in the health sector. A Commission spokesperson attributed the delay to several factors including the transition to the new Commission that took office in December 2024 and digestion of updated mission letters for commissioners, which came in September last year. The need to adjust for earlier budget reallocations was also cited, notably a €1 billion diversion from EU4Health to support Ukraine, announced in February 2024. But more troubling for health NGOs is what the new programme confirms: a complete elimination of operating grants - funds that support an organisation's core operations - leaving only action grants, which finance specific projects. 'It does not mean that NGOs will not be able to directly participate. It's just that we are doing the funding now differently,' a Commission spokesperson told Euronews, referring to this new focus on action grants rather than operational ones. But for these organisations, what may appear to be a mere bureaucratic adjustment actually represents a significant structural shift, as much of their core work—such as on digital health and air pollution—does not easily fit into isolated, time-limited projects. Civil society left in 'survival mode' The delay to unveiling the work programme left health civil society organisations already unable to plan or secure interim financing, resulting in staff reductions and suspended operations. 'The absence of operating grants has pushed many in our sector into survival mode, especially for us, as a large organisation that has historically relied on them,' Milka Sokolović, director general of the European Public Health Alliance (EPHA), told Euronews. As one of the largest health-focused civil society groups in Europe, EPHA has been forced to cut its staff by 40% this year due to the uncertainty and reduced funding. It's not alone. EURORDIS, the European organisation representing patients with rare diseases, also criticised the cuts. 'It's deeply regrettable that the EU4Health 2025 Work Programme not only confirms the exclusion of operating grants for health NGOs, but also provides few – if any – alternative funding opportunities for civil society,' said Virginie Bros-Facer, CEO of EURORDIS. "Over the past 20 years, DG SANTE [the Commission's health service] has recognised the value of operating grants as the only funding mechanism that ensures meaningful interaction between civil society and EU institutions," said Florence Berteletti from the European Alcohol Policy Alliance. She added that operating grants represent only a marginal share of the EU health budget—just 1%. With cuts in operating grants, many of these NGOs are expected to struggle to stay afloat, as they will no longer be able to fulfil essential roles. EU, a shrinking space for civil society The funding shortfall comes amid broader concerns that civil society is being sidelined. Right-wing criticism of the Commission's funding of environmental NGOs has created a climate some see as increasingly hostile to non-profit organisations. For Sokolović, the Commission's funding of NGOs exists to balance the influence of wealthier private lobbies. 'It allows us to act as watchdogs for democracy at a time of democratic backsliding. Without it, commercial interests will dominate EU decision-making, unchecked. And I must say — this goes far beyond health,' she said. The other trend is a reduced space for health actions in the EU's priorities compared to the launch of EU4Health in the wake of the COVID-19 pandemic, designed as the EU's first standalone health budget, with €5.3 billion allocated to strengthen the sector. But five years on, and in the absence of core support for NGOs, many are now questioning whether public health remains a true EU priority.
Euronews
2 days ago
- Euronews
EU regulators back twice-yearly HIV injection
European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the course of the epidemic. The jab from the drugmaker Gilead was considered one of the biggest medical breakthroughs of 2024, offering an alternative to daily pills. The drug, called lenacapavir, was 100 per cent effective at preventing the virus in clinical studies. It is a form of pre-exposure prophylaxis (PrEP), which works by preventing the virus from replicating and spreading within the body. It reduces the risk of acquiring HIV among both adults and adolescents. Gilead said the European Medicines Agency's (EMA) advisory committee issued a positive opinion of the drug on Friday, clearing the way for the European Commission to approve the drug in the coming months. 'This milestone reflects our commitment to reimagine HIV prevention in Europe and around the world,' Dr Dietmar Berger, Gilead Sciences' chief medical officer, said in a statement. 'Lenacapavir for PrEP has the potential to become a critical tool for public health, helping to expand prevention options for people who face the highest barriers to care'. While there has been progress in the fight against HIV, cases have been rising. In 2023, there were more than 24,700 new HIV diagnoses in the European Union, Iceland, Liechtenstein, and Norway, up 11.8 per cent from 2022. The US Food and Drug Administration (FDA) also approved the new drug last month. In the EU, Gilead expects to sell it under the name Yeytuo. Gilead has agreed to sell generic versions of the drug in 120 lower-income countries with high HIV rates. But it is not yet clear how widely available it will be after the United States, which has traditionally been a major global health donor, slashed funding earlier this year. The EMA and the European Commission, the EU's executive body, did not immediately reply to requests for comment.
